BP-C1(BP-C1) - 药物靶点：DNA_专利_临床

概要

基本信息

药物类型

小分子化药

别名

BP C1

靶点

DNA

作用方式

抑制剂

作用机制

DNA抑制剂(DNA抑制剂)

治疗领域

肿瘤消化系统疾病内分泌与代谢疾病+ [1]

在研适应症-

非在研适应症

转移性乳腺癌转移性胰腺癌不能切除性胰腺癌

原研机构

Meabco A/S

在研机构-

非在研机构

Meabco A/S

权益机构-

最高研发阶段无进展临床2期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

6

项与 BP-C1 相关的临床试验

NCT03627390

/ Completed临床2期

The Effect of BP-C1 in Treatment of Inoperable Pancreatic Cancer Patients: A Single Centre Pilot Study

The aim of this study is to investigate the short-term effect and tolerability BP-C1 in patients with metastatic pancreatic cancer who has undergone guideline-recommended chemotherapy.

开始日期2014-12-19

申办/合作机构

Meabco A/S

[+2]

NCT03603197

/ Completed临床2期

A Randomized, Double Blind and Placebo Controlled Multicenter Study Comparing BP-C1 and an Equal Looking Placebo in Metastatic Breast Cancer Patients. A Phase IIB Study

The purpose of this study is to determine whether BP-C1 is effective in the short-term treatment of metastatic breast cancer patients who have previously undergone at least three lines of chemotherapy.

开始日期2014-06-05

申办/合作机构

Meabco A/S

[+2]

NCT01861509

/ Completed临床1期

Pharmacokinetic, Pharmacodynamic and Interleukin Profile of Intramuscularly Administered BP-C1 in Women With Metastatic Breast Cancer. A Phase ID Study

This study is an open label, non-randomized phase I single-armed study in women with metastatic breast cancer (MBC) who have previously undergone all available standard chemotherapy regimens. The purpose of the study is to estimate the pharmacokinetics (PK) after single dose and multiple dose of BP-C1, investigate interleukin levels during BP-C1 treatment and assess treatment response according to RECIST criteria.

开始日期2014-01-19

申办/合作机构

Meabco A/S

100 项与 BP-C1 相关的临床结果

登录后查看更多信息

100 项与 BP-C1 相关的转化医学

登录后查看更多信息

100 项与 BP-C1 相关的专利（医药）

登录后查看更多信息

8

项与 BP-C1 相关的文献（医药）

2022-09-01·Journal of trace elements in medicine and biology : organ of the Society for Minerals and Trace Elements (GMS)

Assessment of antitumor activity of BP-C1, a platinum-based anticancer agent with a lignin-derived polymeric ligand, in autochthonous induced and spontaneous carcinogenesis rodent models

Article

作者: Tyndyk, Margarita L ; Gubareva, Ekaterina A ; Pigarev, Sergey E ; Popovich, Irina G ; Yurova, Maria N ; Anisimov, Vladimir N ; Panchenko, Andrey V ; Solovyev, Nikolay D ; Fedoros, Elena I ; Anikin, Ivan V

BACKGROUND:

A standard approach to study the anticancer activity of novel drugs is their testing in animals with inoculated tumors, which has some limitations. An alternative is the use of spontaneous or carcinogen-induced tumor models as they have better translation potential. The carcinogen-induced and transgenic tumor models were used to assess the antitumor activity of BP-C1, a platinum-containing drug with lignin-derived polymeric ligand.

METHODS:

We used female Swiss-H-derived mice and Wistar female rats to induce autochthonous tumors via exposure to benzo[a]pyrene and 1,2-dimethylhydrazine, respectively. Additionally, transgenic HER-2/neu FVB/N female mice, prone to the development of spontaneous mammary carcinomas, were used.

RESULTS:

Antitumor activity of BP-C1 was observed in soft tissue sarcomas, induced by benzo[a]pyrene. The animals treated with BP-C1 exhibited more stabilizations and therapy responses compared to placebo controls. The efficacy of BP-C1 was somewhat reduced compared to cyclophosphamide; however, their combination resulted in an enhanced antitumor effect. For the 1,2-dimethylhydrazine-induced rat colon cancer model, BP-C1 reduced tumor multiplicity by 21-41 %. For mammary adenocarcinomas in HER-2/neu FVB/N mice, short-termed complete responses were observed in the BP-C1 groups with a frequency of 12-13 %, while complete responses were absent in the placebo group.

CONCLUSION:

The results acquired indicated a wide spectrum of antitumor activity of BP-C1.

2017-11-21·Oncotarget

Results and prospects of development of new polyphenolic drugs for cancer patients

Article

作者: Scherbakov, Alexander M. ; Larsen, Stig ; Bykov, Vladimir N. ; Fedoros, Elena I. ; Anisimov, Vladimir N. ; Malek, Anastasia V. ; Baldueva, Irina A. ; Lofberg, Stig ; Belyaev, Alexey M. ; Perminova, Irina V. ; Drobyshev, Evgeny Yu. ; Panchenko, Andrey V. ; Nielsen, Tea Kirkegaard

The conference "Results and prospects of development of new polyphenolic drugs for cancer patients" took place at the N.N. Petrov National Medical Research Center of Oncology (PNMRCO) on May 31, 2017, and gathered researchers involved in development and evaluation of medicinal products based on the novel lignin-derived soluble polyphenolic polymer BP-Cx-1. BP-Cx-1 is the platform for a portfolio of innovative pharmacological products such as BP-C1, BP-C2 and BP-C3.

Breast cancer (Dove Medical Press)

BP-C1 in the treatment of patients with stage IV breast cancer: a randomized, double-blind, placebo-controlled multicenter study and an additional open-label treatment phase [Corrigendum]

作者: Larsen, Stig ; Manikas, Alexey ; Poddubudkaya, Elena ; Trishkina, Ekaterina ; Matrosova, Marina ; Srimuninnimit, Vichien ; Lindkær-Jensen, Steen ; Butthongkomvong, Kritiya

[This corrects the article on p. 179 in vol. 6, PMID: 25473312.].

100 项与 BP-C1 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
转移性胰腺癌	临床2期	埃及	Meabco A/S	2014-12-19
不能切除性胰腺癌	临床2期	埃及	Meabco A/S	2014-12-19
转移性乳腺癌	临床2期	俄罗斯	Meabco A/S	2012-12-24
转移性乳腺癌	临床2期	泰国	Meabco A/S	2012-12-24

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03603197 (Pubmed) 人工标引	临床2期	转移性乳腺癌	31	BP-C1	窪製遞淵窪簾範鬱鹹憲(鹽糧鬱廠窪顧膚淵餘築) = 鏇膚廠觸鑰簾窪繭壓鹹顧壓顧醖憲壓顧糧蓋餘 (簾鏇鹽鹽鹽襯餘齋齋糧 ) 更多	积极	2019-01-14
				Placebo	窪製遞淵窪簾範鬱鹹憲(鹽糧鬱廠窪顧膚淵餘築) = 膚鑰憲憲選鹽餘壓憲積顧壓顧醖憲壓顧糧蓋餘 (簾鏇鹽鹽鹽襯餘齋齋糧 ) 更多
ASCO2017	N/A	不能切除性胰腺癌	12	BP-C1	醖願鏇齋鹽獵範鹹淵壓(構餘窪窪蓋糧鹽顧鹽夢) = 夢醖簾憲齋壓餘網鹽繭簾簾顧製構遞鑰鹹願觸 (簾鹹製獵艱廠繭襯壓積, 42.8–94.5) 更多	积极	2017-05-30
Pubmed \| Breast Cancer (Dove Med Press)	N/A	转移性乳腺癌	30	BP-C1	鑰鏇襯範遞範壓餘觸積(範蓋繭積糧憲範廠製窪) = few adverse events, which were mainly mild and manageable 構襯糧簾醖遞蓋襯積觸 (廠積繭鏇鏇簾範製壓製 )	积极	2014-11-01
				Placebo
ASCO2014	N/A	转移性乳腺癌	-	BP-C1	艱糧廠鑰製顧淵醖壓壓(範淵簾糧構鏇願憲選觸) = Differences in increase in QOL in favor of BP-C1 were detected for all variables 鑰繭艱夢願範願積範構 (鹽糧願鬱夢壓願範築醖 )	积极	2014-05-20
				Placebo